ACTIVE

TAKEDA BELGIUM

Export PDF

Financial year 2025 · Closed on 31/03/2025

Net result4,2 M €-61,9 %over 1 year
Revenue201,4 M €+12,0 %over 1 year
Equity52,6 M €+8,6 %over 1 year
Workforce78,6 ETP+2,9 %over 1 year

Identity

Source · BCE/KBO

TAKEDA BELGIUM is a Public limited company incorporated in 1945. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Zaventem. It employs on average 78,6 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0403.054.202
Incorporation
11/06/1945
Legal form
Public limited company
Registered office
Da Vincilaan 7
1930 Zaventem · FlandreSee on map
Contributed capital
5 577 855,00 €
Latest accounts
31/03/2025
Average workforce
78,6 ETP
Joint committees (3)
  • 116
  • 200
  • 207
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHigh revenue

Financials

Source · NBB, 19 filings

Trend over 15 financial years

20252024202320222019
Income statement
Revenue201,4 M €179,9 M €160,4 M €141,2 M €138 M €
EBITDA6,9 M €16,5 M €9 M €8,7 M €20,7 M €
Operating result6,4 M €15,7 M €7,7 M €7,1 M €19,9 M €
Net result4,2 M €10,9 M €5,5 M €4,8 M €13,3 M €
Balance sheet
Equity52,6 M €48,4 M €37,5 M €32 M €50 M €
Total assets82,7 M €74,8 M €68,4 M €69,1 M €76,2 M €
Cash88 k €81,5 k €2,2 k €231,2 €–
Debts30 M €26,2 M €30,8 M €36,8 M €25,7 M €
Other
Workforce78,6 ETP76,4 ETP76,3 ETP80,6 ETP84,6 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 50 M€ and 100 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/03/2025

4 active · 16 ended

Active mandates

Bruno Rabillier

Managing director · since 01 septembre 2024 · until 26 septembre 2029

Active
Aline Vandecappelle

Director · since 01 novembre 2023 · until 26 septembre 2029

Active
Michael Nesrallah

Director · since 07 mars 2022 · until 27 juin 2024

Active
Paul De Proft

Director · since 31 mars 2020

Active

Ended mandates

Aline Vandelapelle

Director · since 01 novembre 2023 · until 26 septembre 2029

Ended
Michael Nesrallah

Director · since 07 mars 2022 · until 29 septembre 2027

Ended
Takeda Pharmaceutical International AG

Director · since 15 avril 2020

Represented by Peter Stossel

Ended
Elke Pitomvils

Director · since 31 mars 2020 · until 01 novembre 2023

Ended

Other companies at this address

Da Vincilaan 7 1930 Zaventem
CompanyCBE no.
FORCEA● Active
0883.520.342
IM ASSOCIATES● Active
0464.554.477
IQVIA Cancer Research● Active
0763.914.095
IQVIA RDS & INTEGRATED SERVICES BELGIUM● Active
0459.151.577
IQVIA Solutions Belgium● Active
0400.502.211
Orifarm Healthcare● Active
0755.731.948
REDPHARMA● Active
0824.819.011

Full financial information

Source · NBB
202520242023202220212020
Type of accountFull modelFull modelFull modelFull modelFull modelFull model
Start of the financial year01/04/202401/04/202301/04/202201/04/202101/04/202001/04/2019
Closing of the financial year31/03/202531/03/202431/03/202331/03/202231/03/202131/03/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date09/10/202530/09/202416/10/202304/10/202204/10/202116/11/2020
General meeting24/09/202525/09/202427/09/202328/09/202229/09/202123/10/2020
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 19 filings
ModelClosingGeneral meetingFiledLanguageDocument
Full model31/03/202524/09/202509/10/2025DutchPDF
Full model31/03/202425/09/202430/09/2024DutchPDF
Full model31/03/202327/09/202316/10/2023DutchPDF
Full model31/03/202228/09/202204/10/2022DutchPDF
Full model31/03/202129/09/202104/10/2021DutchPDF
Full model31/03/202023/10/202016/11/2020DutchPDF
Full model31/03/201925/09/201918/10/2019DutchPDF
Full model31/03/201828/09/201805/10/2018DutchPDF
Full model31/03/201706/10/201712/10/2017DutchPDF
Full model31/03/201624/08/201614/09/2016FrenchPDF
Full model31/03/201530/09/201521/10/2015FrenchPDF
Full model31/03/201402/07/201414/07/2014FrenchPDF
Full model31/03/201303/07/201315/07/2013FrenchPDF
Full model31/03/201204/07/201210/07/2012FrenchPDF
Full model31/12/201004/05/201127/05/2011FrenchPDF
Full model31/12/200905/05/201001/06/2010FrenchPDF
Full model31/12/200806/05/200902/06/2009FrenchPDF
Full model31/12/200722/05/200816/06/2008FrenchPDF
Full model31/12/200602/05/200711/06/2007FrenchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 50 M€ and 100 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/03/2025

4 active · 16 ended

Active mandates

Bruno Rabillier

Managing director · since 01 septembre 2024 · until 26 septembre 2029

Active
Aline Vandecappelle

Director · since 01 novembre 2023 · until 26 septembre 2029

Active
Michael Nesrallah

Director · since 07 mars 2022 · until 27 juin 2024

Active
Paul De Proft

Director · since 31 mars 2020

Active

Ended mandates

Aline Vandelapelle

Director · since 01 novembre 2023 · until 26 septembre 2029

Ended
Michael Nesrallah

Director · since 07 mars 2022 · until 29 septembre 2027

Ended
Takeda Pharmaceutical International AG

Director · since 15 avril 2020

Represented by Peter Stossel

Ended
Elke Pitomvils

Director · since 31 mars 2020 · until 01 novembre 2023

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Mandates18/12/2025
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates07/11/2025
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates16/01/2025
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates30/09/2024
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates25/07/2024
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates22/11/2023
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates31/10/2023
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates11/04/2022
    ONTSLAGEN - BENOEMINGEN
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 25/09/2025
    reconductionPaul DE PROFT — bestuurder
  2. 25/09/2025
    unknownVANDECAPPELLE Aline — bestuurder
  3. 25/09/2025
    unknownRABILIER Bruno — bestuurder en gedelegeerd bestuurder
  4. 2025
    Annual accounts 20254,2 M €↓
  5. 01/01/2025
    nominationBruno Rabilier — gedelegeerd bestuurder
  6. 01/09/2024
    nominationBruno Rabilier — bestuurder
  7. 01/09/2024
    unknownPaul De Proft — bestuurder en gedelegeerd bestuurder
  8. 01/09/2024
    unknownAline Vandecappelle — bestuurder
  9. 2024
    Annual accounts 202410,9 M €↑
  10. 01/11/2023
    nominationAline Vandecappelle — bestuurder
  11. 27/09/2023
    reconductionKPMG Bedrijfsrevisoren BV — commissaris
  12. 2023
    Annual accounts 20235,5 M €↑
  13. 2022
    Annual accounts 20224,8 M €↓
  14. 07/03/2022
    revocationPaul de Proft — machten van dagelijks bestuur
  15. 2019
    Annual accounts 201913,3 M €↓
  16. 2018
    Annual accounts 201813,7 M €↓
  17. 2017
    Annual accounts 201727,9 M €↑
  18. 2016
    Annual accounts 201611,1 M €↑
  19. 2015
    Annual accounts 2015-7,3 M €↓
  20. 2014
    Annual accounts 20144,2 M €↓
  21. 2013
    Annual accounts 20135,2 M €↑
  22. 2012
    Annual accounts 20124,2 M €↑
  23. 2010
    Annual accounts 20102,5 M €↓
  24. 2009
    Annual accounts 20093,2 M €↓
  25. 2008
    Annual accounts 20086,9 M €
  26. 11/06/1945
    IncorporationPublic limited company